The concepts of partial recovery and remission have become increasingly important for the evaluation of the effectiveness of schizophrenia therapeutics. The relationship of baseline symptoms and changes in symptoms to remission of psychosis was evaluated. Fifty-six outpatients with residual schizophrenia completed a double-blind trial of olanzapine versus haloperidol and were then enrolled into a one-year open-label trial of olanzapine. Out of these 56 subjects, 13 (23%) met remission criteria at the beginning of the open-label treatment and were excluded. During the one-year study, 7/43 (16%) subjects met remission criteria. These subjects had significantly lower baseline ratings for tardive dyskinesia (TD) than subjects who did not achieve remission (1.8 ± 1.5 vs. 4.2 ± 4.6, P = 0.03). As expected, remitted subjects had significantly greater improvements in Brief Psychiatric Rating Scale total scores, positive subscale scores and scale for the Assessment of Negative Symptoms total scores. Remitted subjects also experienced a significantly greater improvement in depressive symptoms (P = 0.001), activation (P = 0.005), and Clinical Global Impressions scores (P < 0.001), as well as greater improvements in extrapyramidal symptoms (P = 0.007) and TD (P < 0.001). These results suggest that the relationship of depressive symptoms and improved side effects to the construct of remission in schizophrenia may deserve special attention. Future studies should aim to relate remission criteria to functional outcomes, cognition, and other important symptom domains.
Amminger GP Resch F Mutschlechner R Freidrich MH Ernst E (1997) Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur Child Adolesc Psychiatry6: 212–218.
2.
Andreasen NC (1989) The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry7(Suppl): 49–58.
3.
Andreasen NC Carpenter WT Kane JM Lasser RA Marder SR Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry162: 441–449.
4.
Ascher-Svanum H Zhu B Faries D Kinon BJ Kane JM (2005) Type of symptom remission and treatment outcomes in the long-term treatment of patients with schizophrenia. Neuropsychopharmacology30(Suppl 1): S114.
5.
Auslander LA Jeste DV (2004) Sustained remission of schizophrenia among community dwelling older outpatients. Am J Psychiatry161: 1490–1493.
6.
Barbarotto R Castignoli G Pasetti C Laiacona M (2001) Global cognitive decline in schizophrenia with remission of symptoms. Brain Cogn46: 29–34.
7.
Bellack AS (2006) Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull32: 432–442.
8.
Buchanan RW Ball MP Weiner E Kirkpatrick B Gold JM McMahon RP (2005) Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry162: 124–129.
9.
Cassidy SL Thaker GK Summerfelt A Tamminga CA (1997) The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Res70: 21–37.
10.
Chakos MH Alvir JM Woerner MG Koreen A Geisler S Mayerhoff D (1996) Incidence and correlates of tardive dyskinesia in first-episode schizophrenia. Arch Gen Psychiatry53: 313–319.
11.
Curtis CE Calkins ME Grove WM Keil KJ Iocono WG (2001) Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree relatives. Am J Psychiatry158: 100–106.
12.
Dunayevich E Sethuraman G Enerson M Taylor CC Lin D (2006) Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res86: 300–308.
13.
Eaton WW Thara R Federman E Tien A (1998) Remission and relapse in schizophrenia: the Madras longitudinal study. J Nerv Ment Dis186: 357–363.
14.
ECDEU Assessment Manual for Psychopharmacology (1976). In: W Guy (ed), Clinical Global Impressions.Rockville, MD: US Department of Health, Education, and Welfare, pp. 76–338.
15.
Emsley R Rabinowitz J Medori R , Early psychosis global working group (2007) Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res89: 129–139.
16.
Gold JM Goldberg RW McNary SW Dixon LB Lehman AF (2002) Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry159: 1395–1402.
17.
Hamilton M (1976) Hamilton Psychiatric Rating Scale for Depression. In: W Guy (ed), ECDEU Assessment Manual for Psychopharmacology.Rockville, MD: US Department of Health, Education and Welfare, pp. 179–192.
18.
Harrow M Grossman LS Jobe TH Herbener ES (2005) Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr Bull31: 723–734.
19.
Harvey PF Harvey PD Bowie CR Loebel A (2007) The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 94: 99–106.
20.
Hawk AB Carpenter WT Strauss JS (1975) Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry32: 343–347.
21.
Heinrichs DW Hanlon TE Carpenter WT (1984) The Quality of Life Scale: An instrument of rating the schizophrenic deficit syndrome. Schizophr Bull10: 338–398.
22.
Helldin L Kane JM Karilampi U Norlander T Archer T (2006) Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res40: 738–745.
23.
Ho BC Andreasen NC Flaum M Nopoulos P Miller D (2000) Untreated initial psychosis: its relation to quality of life and symptoms remission in first-episode schizophrenia. Am J Psychiatry157: 808–815.
24.
Kopelowicz A Liberman RP Ventura J Zarate R Mintz J (2005) Neurocognitive correlates or recovery from schizophrenia. Psychol Med35: 1165–1173.
25.
Lasser RA Bossie CA Gharabawi GM Kane JM (2005) Remission in schizophrenia: results from a 1-yar study of long-acting risperidone injection. Schizophr Res77: 215–227.
26.
Leucht S Lasser R (2006) The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry39: 161–170.
27.
Lieberman JA Koreen AR Chakos M Sheitman B Woerner M Alvir JM (1996) Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry57(Suppl 9): 5–9.
28.
Liberman RP Kopelowicz A (2005) Sustained remission of schizophrenia. Am J Psychiatry162: 1763–1764.
29.
Liberman RP Kopelowicz A Venture J Gutkind D (2002) Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry14: 256–272.
30.
McIntyre RS Fallu A Konarski JZ (2006) Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther28: 1882–1891.
31.
Murray RM Van Os J (1998) Predictors of outcome in schizophrenia. J Clin Psychopharmacol18(2 Suppl 1): 2S–4S.
32.
Overall JE Gorham DR (1962) The Brief psychiatric rating scale. Psychol Rep10: 799–812.
33.
34.
Remington G Kapur S (2005) Remission: What’s in a name. Am J Psychiatry162: 2393–2394.
35.
Resnick SG Fontana A Lehman AF Rosenheck RA (2005) An empirical conceptualization of the recovery orientation. Schizophr Res75: 119–128.
36.
Robinson DG Woerner MG McMeniman M Mendlowitz A Bilder RM (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry161: 473–479.
37.
Simpson GM Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand212 (Suppl 44): 11–19.
38.
Smith TE Hull JW Huppert JD Silverstein SM (2002) Recovery from psychosis in schizophrenia and schizoaffective disorder: symptoms and neurocognitive rate-limiters for the development of social behavior skills. Schiozophr Res55: 229–237.
39.
Tan YL Zhou DF Zhang XY (2005) Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res74: 263–270.
40.
Van Os J Burns T Cavallaro R Leucht S Peuskens J Helldin L (2006) Standardized remission criteria in schizophrenia. Acta Psychiatr Scand113: 91–95.
41.
Yen CF Chen CS Yeh ML Yen JY Ker JH Yang SJ (2002) Comparison of insight in patients with schizophrenia and bipolar disorder in remission. J Nerv Ment Dis190: 847–849.
